David C Fritzinger Selected Research

Aftercare (After-Treatment)

12/2009

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David C Fritzinger Research Topics

Disease

4	Reperfusion Injury 03/2015 - 01/2008
2	Hemophilia A (Haemophilia) 01/2018 - 10/2014
2	Macular Degeneration (Age-Related Maculopathy) 10/2014 - 01/2010
2	Myocardial Ischemia (Ischemic Heart Diseases) 12/2009 - 01/2008
1	Postoperative Pain 01/2016
1	Pain (Aches) 01/2016
1	Infections 01/2016
1	Endocrine System Diseases (Endocrine Diseases) 01/2016
1	Autoimmune Diseases (Autoimmune Disease) 01/2016
1	Substance-Related Disorders (Drug Abuse) 01/2016
1	Neuralgia (Stump Neuralgia) 01/2016
1	Vascular Diseases (Vascular Disease) 03/2015
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 10/2014
1	Lymphoma (Lymphomas) 12/2009
1	Ascites 12/2009
1	Experimental Arthritis 01/2008
1	Neoplasms (Cancer) 05/2005

Drug/Important Bio-Agent (IBA)

8	Complement System Proteins (Complement)IBA 01/2016 - 05/2005
5	cobra venom factorIBA 01/2018 - 05/2005
2	Factor VIII (Coagulation Factor VIII)IBA 01/2018 - 10/2014
2	Proteins (Proteins, Gene)FDA Link 01/2008 - 05/2005
1	Neutralizing AntibodiesIBA 01/2018
1	AnaphylatoxinsIBA 01/2018
1	Complement C3 (C3 Complement)IBA 01/2018
1	Therapeutic UsesIBA 03/2015
1	Retinaldehyde (Retinal)IBA 01/2010
1	Rituximab (Mabthera)FDA Link 12/2009
1	Monoclonal AntibodiesIBA 12/2009

Therapy/Procedure

3	Therapeutics 01/2016 - 12/2009
1	Aftercare (After-Treatment) 12/2009